The pro-angiogenic effect of human-derived ILC2s can be inhibited by α-CGRP antibody or CGRP receptor antibody. (A) In vitro co-culture experiment of human-derived ILC2s and HUVECs (created with https://BioRender.com). (B) Human-derived ILC2s expressing α-CGRP. (C–E) Human-derived cell assay: In vitro HUVEC sprouting experiment, quantification of the number and length of sprouts per spheroid (n = 5). Scale bar, 100 µm. Data are shown as bar plots (SD, median), analyzed by one-way ANOVA with Tukey’s multiple comparisons. In C, ILC2s versus ILC2s+Ri.: ***P = 0.0002. ILC2s vs ILC2s+Fr.: ***P = 0.0005. ILC2s+Ri. vs ILC2s+Fr.: P > 0.05. In D, ****P < 0.0001, ns indicates P > 0.05. (F–H) Human-derived cell assay: In vitro HUVEC tube formation experiment, quantification of node number and branch length of tubular structures (n = 5). Ri, rimegepant; Fr, fremanezumab. Scale bar, 250 µm. Data are shown as bar plots (SD, median), analyzed by one-way ANOVA with Tukey’s multiple comparisons. ****P < 0.0001, ns indicates P > 0.05.